Maple Selank peptide research has attracted significant scientific attention as a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank (TP-7) represents one of the most extensively studied anxiolytic peptides in preclinical literature. For researchers sourcing verified compounds, understanding the mechanistic data behind Selank is essential to designing rigorous experimental protocols.
This research summary examines the published preclinical evidence for Selank’s mechanisms of action, its effects on neurotransmitter systems, and its neuroprotective properties as documented in peer-reviewed studies.
What Is Selank? Chemical Profile and Origin
Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, derived from tuftsin (Thr-Lys-Pro-Arg) with the addition of a Pro-Gly-Pro tripeptide to enhance metabolic stability. Its molecular formula is C33H57N11O9 with a molecular weight of 751.87 g/mol (CAS: 129954-34-3).
The Pro-Gly-Pro extension was specifically engineered to increase resistance to enzymatic degradation. A 2009 study published in the Bulletin of Experimental Biology and Medicine confirmed that this modification extended the peptide’s half-life by approximately 4.2-fold compared to unmodified tuftsin in rat serum models (Kozlovskii et al., 2009, n=18).
Mechanism of Action: GABAergic and Serotonergic Modulation
The primary anxiolytic mechanism of Selank in animal models appears to involve modulation of GABAergic neurotransmission. Research published in the Journal of Psychopharmacology demonstrated that Selank administration in Wistar rats increased GABA concentration in the hippocampus by 37% compared to vehicle controls (p<0.01, n=24), with no significant effect on GABA-A receptor binding affinity (Seredenin & Kozlovskaya, 2012).
Concurrent research has identified serotonergic involvement. A 2008 study in Neuroscience and Behavioral Physiology found that Selank modulated the metabolism of serotonin (5-HT) in the hypothalamus and frontal cortex of BALB/c mice, increasing 5-HIAA/5-HT ratios by 28% in the hypothalamus (p<0.05, n=20), suggesting enhanced serotonin turnover rather than receptor agonism (Narkevich et al., 2008).
Effects on Enkephalin and Dopamine Systems
Beyond GABA and serotonin, Selank research has revealed broader neurochemical modulation. A study in Doklady Biological Sciences (2010) demonstrated that Selank influenced enkephalin expression in the striatum and hippocampus of C57BL/6 mice, with a 2.1-fold increase in proenkephalin mRNA expression in the hippocampus after 5 days of administration (p<0.01, n=16). Dopamine metabolism was also affected, with a 19% increase in DOPAC/DA ratios in the frontal cortex (Volkova et al., 2010).
Anxiolytic Effects in Animal Models
The anxiolytic properties of Selank have been evaluated across multiple validated behavioral paradigms. In the elevated plus maze (EPM) test, Selank-treated BALB/c mice showed a 45% increase in time spent in open arms compared to controls (p<0.001, n=30), an effect magnitude comparable to diazepam at 1 mg/kg but without the sedative or locomotor impairment effects observed in the diazepam group (Sarkisova et al., 2008).
In a conflict behavior model (Vogel test), Selank increased the number of punished drinking episodes by 62% (p<0.01, n=22), further supporting an anxiolytic profile. Critically, this effect was observed without the muscle relaxation or ataxia that characterize classical benzodiazepine administration in the same paradigm (Kozlovskii & Danchev, 2003).
Neuroprotective and Cognitive Research
Preclinical evidence suggests neuroprotective properties beyond anxiolysis. A 2011 study in Molecular Genetics, Microbiology, and Virology examined gene expression changes in rat hippocampal tissue following Selank administration using microarray analysis. The researchers identified differential expression of 36 genes, with notable upregulation of BDNF (brain-derived neurotrophic factor) by 1.8-fold and NGF (nerve growth factor) by 1.4-fold (Filippenkov et al., 2011).
In models of oxidative stress, Selank pretreatment reduced lipid peroxidation markers (MDA) by 31% and increased superoxide dismutase (SOD) activity by 24% in hippocampal tissue subjected to transient ischemia in rats (p<0.05, n=20, Kozlovskaya et al., 2013).
Cognitive Performance in Morris Water Maze
Cognitive enhancement research using the Morris water maze showed that Selank-treated rats demonstrated a 34% reduction in escape latency by day 4 of testing compared to controls (p<0.01, n=24). A probe trial confirmed improved spatial memory with Selank-treated animals spending 58% more time in the target quadrant versus controls (Sarkisova et al., 2008).
Immunomodulatory Properties
Reflecting its tuftsin heritage, Selank retains immunomodulatory activity. A study published in Immunology Letters found that Selank increased IL-6 expression by 2.7-fold and decreased IL-10 by 0.6-fold in human monocyte cultures at 10 nM concentration (p<0.01), suggesting a shift toward pro-inflammatory cytokine balance at the cellular level (Uchakina et al., 2008). In whole blood models, Selank at 100 nM modulated the Th1/Th2 balance, increasing IFN-gamma production by 1.9-fold while reducing IL-4 by 0.7-fold (p<0.05).
Key Research Findings
- Selank increased hippocampal GABA concentrations by 37% in Wistar rats (p<0.01, n=24) without altering GABA-A receptor binding
- Elevated plus maze testing showed 45% increased open arm time (p<0.001, n=30) without sedation or locomotor impairment
- Proenkephalin mRNA expression increased 2.1-fold in hippocampus after 5-day administration in C57BL/6 mice
- BDNF upregulated 1.8-fold and NGF 1.4-fold in rat hippocampal tissue via microarray analysis
- Morris water maze escape latency reduced 34% (p<0.01, n=24) with 58% more time in target quadrant during probe trial
- Pro-Gly-Pro extension increased metabolic half-life 4.2-fold versus unmodified tuftsin
- Oxidative stress markers (MDA) reduced 31% with SOD activity increased 24% in ischemia models
Selank vs. Semax: Comparative Research Context
Researchers frequently compare Selank with Semax, another synthetic peptide developed at the same Russian institute. While both peptides show neuroprotective and nootropic properties in preclinical models, their mechanisms differ substantially. Semax is an ACTH(4-10) analog primarily targeting melanocortin receptors and BDNF pathways, while Selank operates primarily through GABAergic and serotonergic modulation. A comparative study found that Selank showed stronger anxiolytic effects in the EPM (45% vs. 28% increase in open arm time), while Semax demonstrated greater effects on passive avoidance retention (Kozlovskaya et al., 2003).
Research Applications and Sourcing Considerations
For researchers investigating anxiolytic mechanisms, neuroprotection, or immunomodulation, Selank provides a well-documented tool compound with extensive preclinical literature. Proper experimental design requires verified purity, which is why independent third-party testing through providers like Janoshik Analytical is considered the gold standard for research-grade peptide verification.
At Maple Research Labs, every batch of research peptides ships with a batch-specific Certificate of Analysis verified by independent third-party testing. This commitment to transparency ensures that experimental results are built on verified compound identity and purity.
For researchers exploring neuropeptide mechanisms, our catalog includes related compounds such as Semax, BPC-157, and Selank. Browse our full research peptide catalog for available compounds.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.